{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:53:08Z","timestamp":1791175988314,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serplulimab, a first-line therapy for extensive-stage small cell lung cancer (ES-SCLC), can cause checkpoint inhibitor pneumonitis (CIP). The clinical features and outcomes of serplulimab-induced CIP in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV chronic obstructive pulmonary disease (COPD) remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>An 80-year-old man with ES-SCLC and preexisting GOLD stage IV COPD received first-line serplulimab plus chemotherapy. After achieving an initial partial response, chemotherapy was discontinued due to reduced tolerance following bacterial pneumonia, and he was continued on serplulimab monotherapy. Three days after the first maintenance dose of serplulimab, he presented with acute severe chest tightness, dyspnea, and hypoxemia and was admitted to the hospital 4 days later. Chest CT revealed new bilateral pulmonary infiltrates. Extensive workup for infection, acute exacerbation of COPD, and tumor progression was negative; the case was ultimately classified as grade 4 serplulimab-induced CIP. He was treated with high-dose methylprednisolone, intravenous immunoglobulin, and empiric anti-infective therapy, with significant clinical improvement. Follow-up CT at 2 months post-discharge showed significant resolution of pulmonary infiltrates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Severe, life-threatening CIP can occur in elderly patients with ES-SCLC and preexisting GOLD stage IV COPD. In this patient, prompt recognition, intensive immunosuppression, and permanent programmed death-1 (PD-1) inhibitor discontinuation contributed to a favorable outcome. Whether preexisting GOLD stage IV COPD confers an increased risk of severe CIP in this understudied population warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1935484","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:36:35Z","timestamp":1791174995000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Serplulimab-induced checkpoint inhibitor pneumonitis in extensive-stage small cell lung cancer with underlying COPD: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiangang","family":"Ju","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Zhejiang University School of Medicine Second Affiliated Hospital Linping Campus","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Zhejiang University School of Medicine Second Affiliated Hospital Linping Campus","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Zhejiang University School of Medicine Second Affiliated Hospital Linping Campus","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Zhejiang University School of Medicine Second Affiliated Hospital Linping Campus","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Zhejiang University School of Medicine Second Affiliated Hospital Linping Campus","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1274","article-title":"Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"19","author":"Yang","year":"2023","journal-title":"Future Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/cac2.70032","article-title":"First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial","volume":"45","author":"Cheng","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-1815","article-title":"First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study","volume":"17","author":"Shi","year":"2025","journal-title":"J Thorac Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2026.1645","article-title":"First-line serplulimab in extensive-stage small cell lung cancer: secondary analysis of the ASTRUM-005 phase 3 randomized clinical trial","volume":"12","author":"Liu","year":"2026","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3892\/ol.2026.15638","article-title":"Immunotherapy retreatment with serplulimab vs. chemotherapy in extensive-stage advanced small cell lung cancer","volume":"32","author":"Gu","year":"2026","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12890-024-03180-w","article-title":"The impact of chronic obstructive pulmonary disease on the risk of immune-related pneumonitis in lung cancer patients undergoing immunotherapy: a systematic review and meta-analysis","volume":"24","author":"Li","year":"2024","journal-title":"BMC Pulm Med"},{"key":"B15","unstructured":"Common terminology criteria for adverse events (CTCAE). Version 5.0\n          \n          \n          \n          2017"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2026.44.16_suppl.e20596","article-title":"Risk of immune checkpoint inhibitor\u2013related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease: a propensity score\u2013matched analysis","volume":"44","author":"Habbas","year":"2026","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-356","article-title":"The safety and effectiveness of immune checkpoint blockade in lung cancer with COPD: a systematic review and meta-analysis","volume":"17","author":"Wang","year":"2025","journal-title":"J Thorac Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01267-6","article-title":"A risk-scoring model for severe checkpoint inhibitor-related pneumonitis: a case-control study","volume":"43","author":"Deng","year":"2023","journal-title":"Clin Drug Investig"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15471","article-title":"First-line chemoimmunotherapy for patients with small-cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis","volume":"15","author":"Li","year":"2024","journal-title":"Thorac Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61112064","article-title":"Checkpoint inhibitor pneumonitis: key insights for pulmonologists","volume":"61","author":"Serra","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698832","article-title":"Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.018306","article-title":"Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Drobni","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152866","article-title":"Serum KL-6 levels reflect the severity of interstitial lung disease caused by immune checkpoint inhibitors","volume":"230","author":"Li","year":"2025","journal-title":"Immunobiology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01899-8","article-title":"First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis","volume":"26","author":"Hotta","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010114","article-title":"Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis","volume":"12","author":"Matsukane","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/mcp.0000000000000975","article-title":"Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease","volume":"29","author":"Azhar","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, Version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/etm.2024.12670","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: how, when and why to diagnose and manage (review)","volume":"28","author":"Lavalle","year":"2024","journal-title":"Exp Ther Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000538429","article-title":"Lethal immune-related pneumonitis after durvalumab therapy for small cell lung cancer: a first case in China","volume":"17","author":"Li","year":"2024","journal-title":"Case Rep Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1935484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:37:00Z","timestamp":1791175020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1935484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1935484"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1935484","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1935484"}}